This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRK) Outperforming Other Medical Stocks This Year?
Stock Market News For Jul 31, 2019
by Zacks Equity Research
Stocks closed in the red on Tuesday after Trump???s renewed attacks on China diminished investor???s hopes of a positive outcome from trade talks.
Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.
Economic and Earnings Date Deluge
by Zacks Equity Research
Economic and Earnings Date Deluge
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More
by Mark Vickery
Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Stock Market News For Jul 30, 2019
by Zacks Equity Research
Ongoing U.S. and China trade negotiations and expectations around a Fed rate hike kept benchmarks on a tight leash on Monday.
Merck (MRK) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 12.07% and 7.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?
by Christopher Vargas
Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.
Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the second quarter, primarily on robust sales of Opdivo and Eliquis. However, pipeline setbacks are a concern.
AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
What to Expect from Sanofi's (SNY) Q2 Earnings
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.
Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $81.21 in the latest trading session, marking a -0.22% move from the prior day.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Top Ranked Growth Stocks to Buy for July 22nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 22nd
Caterpillar (CAT) Set to Report Q2 Earnings: What to Expect
by Christopher Vargas
Caterpillar (CAT) is a company that has had somewhat of a quiet year, with shares up 7.7% year-to-date.
Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
by Zacks Equity Research
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.